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Introduction
Sepsis is a systemic inﬂammatory response syndrome (SIRS)
triggered by a suspected or veriﬁed pathogen or its product;1
our understanding of its pathomechanism has been on the
rise.2,3 The septic process is an extremely complex, simulta-
neous interplay of proinﬂammatory and anti-inﬂammatory
responses.4–6 The direction, extent, and magnitude of the
host response are determined, on the one hand, by patient-
speciﬁc factors (e.g., genetic predisposition, age, vaccination
status, comorbidity, severe injury, medication taken, use of
invasive equipment) and, on the other hand, by virulence
factors of the pathogen (mostly bacteria, also viruses, fungi,
parasites).7–9 The disease process has an effect on practically
all organ systems; sepsis is often accompanied by the dis-
ruption of cardiovascular function, intravascular volume
status, respiratory function, immune/inﬂammatory regula-
tion, renal function, coagulation, and hepatic function.10
Childhood sepsis is a global health problem, with incidence
and outcomes varying across regions.11 Sepsis is one of
the leading causes of death in children;12 its mortality is
between 2 and 10%,13–15 which is much lower than in
adults.16 Hospital mortality in the United States was found
to be 2% in healthy children, and 8% in patients suffering from
chronic diseases.12 For more than two-thirds of the cases,
airway or bloodstream infections are identiﬁed in the back-
ground.11,17,18 Themost vulnerable pediatric groups include
preterm newborns, infants, sufferers from hereditary or
acquired immune deﬁciencies, chronic debilitating medical
conditions, severe trauma victims, and those recovering
from major surgery or implanted with invasive medical
equipment.19,20 Early detection and adequate ﬁrst line treat-
ment are essential: every single hour spent in hypotension
and with capillary reﬁll longer than 3 seconds doubles the
chance of mortality.21 Thanks to a therapeutic strategy that
emphasizes early diagnosis, aggressive ﬂuid therapy, and
vasoactive support, as well antibiotic treatment as early
as possible, the mortality of childhood sepsis is gradually
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Abstract Sepsis remains one of the leading causes of childhood mortality today, although
survival has substantially improved, thanks to an ever deeper and more thorough
understanding of sepsis pathophysiology, developments in vaccination and intensive
therapy, and goal-directed therapeutic approaches. The key to successful therapy is
early recognition and antibiotic treatment, as well as supportive therapy aimed at
correcting circulatory, respiratory, and metabolic derangements as soon as possible.
Diagnosis and management of childhood sepsis mainly evolves along the path of
studies conducted in adult patients; however, their applicability is limited due to a
variability of cardiovascular and immune responses in each age group. In addition to
childhood characteristics of hemodynamic responses in sepsis, this review looks at
major areas of pediatric sepsis therapy, with the intention of providing bedside
clinicians with pointers useful in their day-to-day work.
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decreasing;22 however, a growing number of children
with predisposing comorbidities and a rise in sepsis pre-
valence due to the spread of multidrug resistant pathogens
continue to challenge health care providers worldwide.11
The objective of this review is to provide a summary of the
clinical management of childhood sepsis and septic shock.
Diagnosis
Historically, the term sepsis was widely used in relation to a
diverse group of syndromes, which often confused clini-
cians.23 In 1992, as part of standardization efforts for the
deﬁnition, the American College of Chest Physicians and
the Society of Critical Care Medicine introduced the term
systemic inﬂammatory response syndrome, deﬁned as a
widespread inﬂammatory response that may or may not
be associated with infection.24 In 2005, the International
Pediatric Consensus Conference adapted the deﬁnitions of
SIRS, sepsis, and other related terms (►Tables 1–2) to pedia-
tric age groups (►Table 3) by introducing age-speciﬁc heart
rate, respiratory rate, and white blood cell count cutoffs
(►Table 4). In addition to facilitating observational study
design and the assessment of various therapeutic interven-
tions in clinical trials, this set of distinct deﬁnitions (sepsis,
severe sepsis and septic shock, organ failure) serves as a
guide to clinicians in severity assessment, progression mon-
itoring, and treatment response evaluation.25,26 However, it
is important to note that the diagnosis of childhood sepsis
should not be conﬁned to a predeﬁned set of pathophysio-
logical and laboratory deviations: in an observational study
at an academic medical center, only two-thirds of patients
under the age of 18 years treated for sepsis or septic shock
satisﬁed the strict requirements of the consensus system of
criteria.27 Lately, more and more clinicians question the
usefulness of SIRS criteria in sepsis and call for separate
sets of deﬁnitions for clinical versus research use.28,29 In
February 2016, new deﬁnitions and clinical criteria of adult
sepsis and septic shock were introduced at the 45th Annual
Critical Care Congress.30
Medical conditions elicited by any sort of proven or
presumed pathogens are deﬁned as infections. Infection
can be conﬁrmed by positive bacterial culture, tissue stain,
or polymerase chain reaction (PCR) test. Infection is presum-
able in certain clinical syndromes (e.g., fever and coughing,
appearance of petechiae and purpurae accompanied by
hemodynamic instability, meningism, abscess, organ per-
foration); it should also be suspected when consistent
with laboratory or imaging ﬁndings (e.g., pulmonary inﬁl-
tration on chest X-ray, presence of leukocytes in normally
sterile body ﬂuids).1
In a great majority of sepsis cases, the site of infection is
likely to be identiﬁed through medical history, physical ex-
amination, laboratory tests, and various imaging studies. To
identify the pathogen, it is recommended to collect two
peripheral blood cultures (both aerobic and anaerobic) prior
to treatment, and an additional sample from any intravascular
tubes in place for more than 48 hours.31–33 The positive
predictive value of testing can be improved, and contamina-
tion rates reduced, throughproper samplingof at least 1mLor,
for older children, 3–10 mL of blood33–36 by a trained phle-
botomist or experienced blood culture team37–39 using sterile
latex gloves and best-practice antisepsis.40 In an effort to not
cause pain or more discomfort, pediatricians often use intra-
venous catheters for blood culture sampling;41 however,
Table 1 Deﬁnitions of SIRS, infection, sepsis, severe sepsis, and septic shock
SIRS The presence of at least two of the following four criteria, one of which must be abnormal temperature or
leukocyte count:
Core temperature of >38.5°C or <36°C
Tachycardia, deﬁned as a mean heart rate >2 SD above normal for age in the absence of external
stimulus, chronic drugs, or painful stimuli; or otherwise unexplained persistent elevation over a 0.5- to
4-h period or for children <1 y old: bradycardia, deﬁned as a mean heart rate <10th percentile for age in
the absence of external vagal stimulus, beta-blocker drugs, or congenital heart disease; or otherwise
unexplained persistent depression over a 0.5-h time period
Mean respiratory rate >2 SD above normal for age or mechanical ventilation for an acute process not
related to underlying neuromuscular disease or the receipt of general anesthesia
Leukocyte count elevated or depressed for age (not secondary to chemotherapy-induced leukopenia)
or >10% immature neutrophils
Infection A suspected or proven (by positive culture, tissue stain, or polymerase chain reaction test) infection
caused by any pathogen or a clinical syndrome associated with a high probability of infection. Evidence of
infection includes positive ﬁndings on clinical exam, imaging, or laboratory tests (e.g., white blood cells in
a normally sterile body ﬂuid, perforated viscus, chest radiograph consistent with pneumonia, petechial or
purpuric rash, or purpura fulminans)
Sepsis SIRS in the presence of or as a result of suspected or proven infection
Severe sepsis Sepsis plus one of the following: cardiovascular organ dysfunction or acute respiratory distress syndrome
or two or more other organ dysfunctions; organ dysfunctions are deﬁned in ►Table 2
Septic shock Sepsis and cardiovascular organ dysfunction as deﬁned in ►Table 2
Abbreviations: SD, standard deviation; SIRS, systemic inﬂammatory response syndrome.
Source: Data from Goldstein et al.1
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avoiding thispracticemight signiﬁcantly reduce thenumberof
false-positive blood cultures.42 Sampling should include other
cultures (e.g., urine, wound exudate, airway secretions, cere-
brospinalﬂuid) as appropriate for the primary infection site.16
Culture growth becomes apparent within a few days;
however, a negative result can only be conﬁrmed after
5 days.43,44 In addition to time issues, another major limiting
factor of the technique is low sensitivity, which can be
aggravated by prior antibiotic treatment and, especially with
pediatric patients, sample volume limitations.45 Challenges
posed by growth-inhibiting bacteriostatic substances, low
pathogen concentrations, and long incubation times of
methods with high detection thresholds can be overcome
using molecular ampliﬁcation techniques.46–48 PCR assays
capableofdetectingup to 25 types of bacteria and fungiwithin
4 to 6 hours are available today;49–53 their application may
open new dimensions in sensitivity and speed, providing
treatment targets at early stages of life-threatening infections.
Developmental Differences in the
Hemodynamic Response to Sepsis in
Children and Adults
One of the major challenges of pediatric critical care med-
icine is dealing with developmental differences that greatly
Table 2 Organ dysfunction criteria
Cardiovascular
dysfunction
Despite administration of isotonic intravenous ﬂuid bolus 40 mL/kg in 1 h:
Decrease in BP (hypotension) 5th percentile for age or systolic BP <2 SD below normal for age
or
Need for vasoactive drug to maintain BP in normal range (dopamine >5 µg/kg/min or dobutamine,
epinephrine, or norepinephrine at any dose)
or two of the following
Unexplained metabolic acidosis: base deﬁcit >5 mEq/L
Increased arterial lactate more than two times upper limit of normal
Oliguria: urine output <0.5 mL/kg/h
Prolonged capillary reﬁll: >5 s
Core to peripheral temperature gap >3°C
Respiratory PaO2/FIO2 < 300 in the absence of cyanotic heart disease or preexisting lung disease
or
PaCO2 > 65 Torr or 20 mm Hg over baseline PaCO2
or
Proven need or >50% FiO2 to maintain saturation >92%
or
Need for nonelective invasive or noninvasive mechanical ventilation
Neurologic Glasgow Coma Score 11
or
Acute change in mental status with a decrease in Glasgow Coma Score 3 points from abnormal baseline
Hematological Platelet count of 80,000/mm3 or a decline of 50% in platelet count from highest value recorded over
the past 3 d (for chronic hematology/oncology patients)
or
International normalized ratio > 2
Renal Serum creatinine more than two times upper limit of normal for age or twofold increase in baseline creatinine
Hepatic Total bilirubin < 4 mg/dL (not applicable for newborn)
or
ALT two times upper limit of normal for age
Abbreviations: ALT, alanine aminotransferase; BP, blood pressure; SD, standard deviation.
Source: Data from Goldstein et al.1
Table 3 Pediatric age groups for severe sepsis deﬁnitions
Newborn 0 d to 1 wk
Neonate 1 wk to 1 mo
Infant 1 mo to 1 y
Toddler and preschool 2–5 y
School age child 6–12 y
Adolescent and young adult 13 to <18 y
Source: Data from Goldstein et al.1
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impact the pathophysiology of sepsis.7 Age-related changes
in heart rate, stroke volume (SV), blood pressure, systemic
vascular resistance (SVR), hemoglobin concentration, meta-
bolic rate, glycogen stores, and protein mass all contribute to
differences in disease progress between children and adults
and to the heterogeneity of cardiovascular and metabolic
responses across pediatric age groups.7,10,54,55 An essential
requirement for successful treatment of childhood sepsis is
the awareness of developmental differences and under-
standing of their effects on the function of various organ
systems.
In septic shock, adult hemodynamic response is initially
characterized by hyperdynamic (high-output) physiology,
including low SVR, tachycardia, and normal or increased
cardiac output (CO), as manifested by ﬂash capillary reﬁll,
bounding pulses, warm and dry extremities, and wide pulse
pressures (“warm” shock).56 Myocardial dysfunction and
reduced CO are compensated in adults through twomechan-
isms: elevation of heart rate and reduction of SVR.7,54,55,57 In
the absence of adequate intervention, progressive SVR re-
duction might result in maldistribution of CO and organ
hypoperfusion. It is a sign of poor prognosis when compen-
sation fails or is insufﬁcient; the risk of death is also higher in
patients whose SVR reduction does not respond to vasopres-
sors.56,58,59 Pediatric septic shock is often accompanied by
hypovolemia; children therefore respond well to aggressive
ﬂuid therapy.55,57 In contrast with the high-CO, low-SVR
adult response, children’s pathophysiology is dominated by
increased SVR and myocardial dysfunction.60–62 Children’s
cardiac reserves are limited. While adults tolerate even
doubling of the resting heart rate to offset a decreased SV
and maintain a sufﬁcient CO fairly well, children do not have
heart rate reserves for a similar increase. Although tachy-
cardia is an important compensatory mechanism in children
as well, the younger the patient, the more likely it is for the
response to become inadequate with a critical heart rate
increase; with the shortening of diastolic ﬁlling time and a
consequential decrease of coronary perfusion, CO may con-
tinue to decline.10,55 In addition to tachycardia, newborns,
infants, and children maintain blood pressure by increasing
SVR; in this case, clinical appearance is characterized by
hypodynamic physiologywith tachycardia, delayed capillary
reﬁll, diminished pulses, cold and mottled extremities
(“cold” shock).10,55,57 Because vasoconstriction intensiﬁes,
hypotension comes as a late-onset sign in childhood septic
shock;61 however, in lack of adequate intervention, further
increase in SVR becomes counterproductive as the disease
progresses since, combined with increased afterload, it
may lead to further reduction in CO, which, in turn, may
cause septic shock decompensation, cardiac failure, and
death.55 Ceneviva et al classiﬁed 50 children with ﬂuid-
and dopamine-resistant septic shock on hemodynamic
data acquired through a pulmonary artery catheter. Most
of the examined patients (58%) was hypodynamic (low CO,
high SVR), 20% showed a hyperdynamic response similar to
that of adults (high CO, low SVR), whereas 22% was detected
with a combination of low CO and low SVR. Four children
showed a complete change in hemodynamic status.61 In
summary, contrary to adults, children produce a hypody-
namic response to septic shockmore often; in addition, their
hemodynamic response as a whole is often heterogeneous
and changes frequently with progress of the disease.
Management of Sepsis in Children
Apart from antimicrobial therapy, management of sepsis is
almost exclusively limited to supportive therapeutic inter-
ventions. The goal-directed approach to septic shock treat-
ment emphasizes rapid restoration of vascular functions,
oxygen delivery, and a therapeutic strategy aimed at early
start antibiotics. Initial resuscitation endpoints should be
reached as soon as possible, preferably within an hour
(►Table 5).16,21,57,63–67 In therapy-resistant shock, constant
advanced hemodynamic monitoring is essential in an inten-
sive care setting. Numerous alternative approaches exist
(SVR, SVR index, SV variation, global end-diastolic volume),
but to date, only measurement of CO and venous oximetry
have been adequately validated and incorporated in clinical
guidelines.68–76 Therapeutic interventions of hemodynamic
support should be directed at maintaining mixed venous
oxygen saturation at 70%, cardiac index between 3.3 and
6 L/minute/m2, and a normal perfusion pressure for age.16,57
Table 4 Age-speciﬁc vital signs and laboratory variablesa
Heart rate (beats/min) Respiratory rate
(breaths/min)
Leukocyte count
(leukocytes 103/mm3)
Systolic blood pressure
(mm Hg)Age group Tachycardia Bradycardia
0 d to 1 wk >180 <100 >50 >34 <65
1 wk to 1 mo >180 <100 >40 >19.5 or <5 <75
1 mo to 1 y >180 <90 >34 >17.5 or <5 <100
2–5 y >140 NA >22 >15.5 or <6 <94
6–12 y >130 NA >18 >13.5 or <4.5 <105
13 to <18 y >110 NA >14 >11 or <4.5 <117
aLower values for heart rate, leukocyte count, and systolic blood pressure are for the ﬁfth and upper values for heart rate, respiration rate, or
leukocyte count for the 95th percentile.
Source: Data from Goldstein et al.1
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Airway Management and Respiratory Support
In septic children, airways and respiration are to be closely
observed since lung compliance andwork of breathingmight
change rapidly and acute lung injury/acute respiratory dis-
tress syndrome (ALI/ARDS) are common complications.77
Respiratory alkalosis of central origin is often detected in
early stage sepsis.With the progress of the disease,metabolic
acidosis, itself a consequence of progressive peripheral cir-
culatory failure,may further deteriorate owing to respiratory
acidosis caused by a consequential disturbance of conscious-
ness and possible pulmonary complications.57 Due to
their generally lower functional residual capacity (FRC)
and limited compensation reserves, septic children, espe-
cially young infants, may require endotracheal intubation
even in early stage disease.16 Respiratory muscles can
demand up to 40% of the total CO; this can be decreased
for the beneﬁt of vital organs through adequate oxygen
therapy, respiratory support and ventilation, or administra-
tion of muscle relaxants;57 however, increased intrathoracic
pressure caused by invasive ventilationmight lead to further
deterioration by impeding venous return, especially if ﬂuid
status of the patient has not been stabilized prior to the
intervention.16
Upon detection of respiratory distress in pediatric sepsis,
and for all children with septic shock, 100% oxygen must
be promptly given to improve peripheral oxygen delivery,
with oxygenation constantlymonitored by pulse oximetry.78
In children receiving any oxygen therapy, once peripheral
circulation has been restored and pulse oximetry is reliable,
hyperoxia should be avoided to prevent potential harm
caused by the production of free radicals.79 In children,
especially infants, whose normal oxygenation cannot be
maintained by oxygen supply, nasal continuous positive
airway pressure can be applied to increase FRC and reduce
work of breathing80 or, as appropriate, bag-valve-mask ven-
tilation should be used while securing venous access before
endotracheal intubation and also during volume resuscita-
tion and peripheral inotropic treatment.16,81
Judgment on the indication for endotracheal intubation
should primarily consider age-speciﬁc respiratory rate, work
of breathing, and level of consciousness; situations that may
require intubation include ARDS, consciousness disorder,
increased intracranial pressure, convulsion persisting after
repeated benzodiazepine administration, central line inser-
tion procedures, invasive hemodynamic monitoring, and
metabolic acidosis expected to respond to slight mechanical
hyperventilation.16,57,81
Mechanical ventilation can be life-saving, but low lung
compliance and/or high peak pressures might lead to venti-
lator-induced lung injury through alveolar overstretching
(volutrauma), repeated alveolar collapse–expansion cycles
(atelectrauma), and oxygen toxicity.82 During ventilation,
lung protective strategies established in adult practice
should be followed.16 In sepsis accompanied by ALI/ARDS,
FiO2 and positive end expiratory pressure should be titrated
for SpO2 to be above 90%,83while still avoiding hyperoxia for
reasons outlined previously. Similar to adult recommenda-
tions, pH should be maintained within the range of 7.3 to
7.45; in certain cases, permissive hypercapnia might by
advantageous unless contraindicated.84,85 Optimal peak
pressure is below 30 cm H2O; the recommended tidal volume
is 4 to 6 mL/kg, with values above 10mL/kg avoided.16,83,84,86
In case conventional ventilation fails, high-frequency oscilla-
tory ventilation can be applied as rescue treatment.87–89
Sedoanalgesia
In the treatment of septic children, sedoanalgesia might be
necessary during endotracheal intubation, mechanical ven-
tilation, invasive interventions (e.g., securing a central line),
and hemodynamic monitoring. Aggressive ﬂuid and vasoac-
tive therapy for early stabilization signiﬁcantly decreases the
risk of hemodynamic collapse during intubation.90 Introduc-
tion and maintenance of sedoanalgesia requires attention to
vasodilatory, direct myocardial depressive, and endogenous
catecholamine suppressor effects of candidate substances
(propofol, thiopental, benzodiazepines, opioids) because
these might cause a deterioration of the patient’s cardiovas-
cular status.57 Etomidate inhibits 11-β-hydroxylase, an
enzyme involved in adrenal steroid hormone synthesis, in
a concentration-dependent and reversible manner.91,92 A
single dose alone can cause adrenal suppression lasting
beyond 24 hours;93,94 increased mortality in childhood
meningococcal septicemia has been reported in relation to
etomidate use,94which is therefore not recommended in the
management of sepsis and septic shock.16,90,95,96 Experi-
mental data suggest a beneﬁt of using ketamine in sepsis
because it decreases interleukin (IL)-6 and tumor necrosis
factor-α synthesis97,98 and increases endogenous norepi-
nephrine release, helping to maintain cardiovascular stabi-
lity as part of a treatment strategy to increase heart rate and
SVR.99 Based on these characteristics, the use of ketamine for
induction is recommended unless contraindications exist.57
Table 5 Therapeutic goals during management of children
with septic shock
Initial therapeutic endpoints:
• Threshold heart rate associated with increased
mortality in critically ill (not necessarily septic) infants
are a HR < 90 bpm or > 160 bpm, and in children
are a HR < 70 bpm or >150 bpm)
• Capillary reﬁll time < 2 s
• Strong distal pulses equal to central pulses
• Warm extremities
• Normal blood pressure for age
• Normal mental status
• Urine output >1 mL/kg/h once effective circulating
volume is restored
• Lactate < 4 mmol/L or 10% decrease per every 1–2 h
Central venous oxygen saturation greater than or equal
to 70%
Cardiac index between 3.3 and 6 L/min/m2
Abbreviations: HR, heart rate.
Source: Data from Brierley et al.57
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Continuous infusion of ketamine with benzodiazepine
not only ensures proper sedation and analgesia but may
also carry deﬁnite beneﬁts in hemodynamically unstable
patients.57,99 To facilitate emergency endotracheal intuba-
tion and to reduce failed laryngoscopy and complication
rates, properly trained and experienced practitioners may
consider using short-acting muscle relaxants in addition
to sedatives;2,78,100 however, continuous use should be
avoided, except in ARDS cases.16
Fluid Therapy
Assessment and management of airways and respiration is
followed by evaluation and optimization of the circulation.
For the treatment of critically ill children, establishing
vascular access as early as possible is essential;78,101–103
however, it often poses a challenge. If executable quickly,
peripheral venous access is acceptable, but the largest and
best accessible vein should be selected.104 The intraosseous
route is a quick and secure alternative also in children and
should be ﬁrst choice in patients with shock.105–109 All
intravenous drugs can be used through the intraosseous
route including infusions, vasoactive and inotropic drugs,
and blood products.
If justiﬁed and not contraindicated, volume resuscitation
must be initiated following placement of vascular access.
Numerous trials have been performed with ﬂuid therapy. In
children with dengue shock syndrome, a survival rate of
almost 100% was observed following ﬂuid resuscitation,
irrespective of composition of the ﬂuid administered.110–112
During the Saline versus Albumin Fluid Evaluation (SAFE)
study conducted for ﬂuid therapy of adults in the intensive
care unit, no difference was found between the use of 4%
albumin and normal saline in 28-day mortality, require-
ments of mechanical ventilation and renal replacement
therapy, time at the intensive care unit and in hospital.113
Given the lack of data in favor of colloid use, crystalloids
should be used ﬁrst line owing to their availability and better
price.110–116
Whilepreviously, theprimaryquestion inﬂuid therapywas
the choice between colloid and crystalloid solutions, today the
focus has shifted to ﬁnding the ideal composition for crystal-
loids.117 Sodium overload, hyperchloremic acidosis, and con-
sequential renal perfusion disorder, each observed during
normal saline use, all potentiallyworsenprognosis in critically
ill patients, especially in those with associated acute kidney
injury.117,118 The use of so-called balanced crystalloids seems
to bemore advantageous,117–121 a common feature ofwhich is
a cation composition more closely matching that of plasma,
and a lower chloride concentration compared with normal
saline. Their invitro isotonicity is ensuredbyother anions such
as lactate, gluconate, and acetate.117,120,121 Owing to their
potassium content and lower osmolarity, their use may be
harmful in hyperkalemia, anuria, and elevated intracranial
pressure.117,122,123 To date, no clinical trial has conﬁrmed
superiority of the childhood use of balanced solutions. As a
summary, with possible complications of sodium or chloride
overload and contraindications of balanced solutions in mind,
the ideal crystalloid choice must be based on an awareness
of the patient’s risk factors and consideration of expected
responses during the use of each solution type.
Current recommendations suggest initiation of ﬂuid re-
suscitationwith the administration of crystalloids (or colloid
equivalent) at 20 mL/kg by push or a pressure bag.16,57,124
Titrated to achieve therapeutic goals (►Table 5), 40 to
60 mL/kg and sometimes even 200 mL/kg dose might be
necessary in the initial phase.16,21,57,125–127 Children with
persistently elevated heart rate unresponsive to ﬂuid resus-
citation should be evaluated for cardiac dysfunction. During
acute stabilization and the use of large-volume ﬂuid, no
increase was detected in the incidence of ARDS and cerebral
edema;57,124,128 however, special attention must be devoted
to signs of ﬂuid overload during ﬂuid resuscitation (in-
creased work of breathing, new-onset rales, gallop rhythm,
hepatomegaly), for which termination of ﬂuid therapy
and administration of inotropic agents and diuretics are
recommended.16,57,129
After shock resuscitation, in cases of ﬂuid overload exceed-
ing 10%when native urine output fails to restoreﬂuid balance
evenwith theuseofdiuretics, peritonealdialysisorcontinuous
renal replacement therapymust be performed.57,130–132 Fluid
loss and hypovolemia due to diffuse capillary leak may persist
for days; maintenance ﬂuid requirements are largely variable,
and ongoing ﬂuid replacement must be performed under
monitoring of perfusion, central venous pressure, CO, and
echocardiographic control.57
Cardiovascular Drug Therapy
Several factors need to be considered during selection and
dosing of cardiovascular drugs; their delayed use signiﬁ-
cantly increases mortality.133,134 Each drug may facilitate
restoration of adequate organ perfusion acting on various
targets, that is, by increasing contractility (inotropy) and
heart rate (chronotropy), or modifying SVR (vasopressor or
vasodilator effect). Pharmacokinetics and pharmacody-
namics of individual drugs are inﬂuenced not only by patient
age but also by organ failure (liver and kidney) developing
during sepsis.57 Again, it is important to note that sepsis and
septic shock are dynamically changing pathologies, often
necessitating modiﬁcation in the dose, or replacement of
medications used, or adding agents with other targets, due to
changes in hemodynamic status of patients.61
Dopamine titrated to 5 to 10 µg/kg/minute is the ﬁrst-
choice inotropic agent in ﬂuid-refractory shock. At doses
above 10 µg/kg/minute, its α-adrenergic effect predomi-
nates, making it beneﬁcial for use in low SVR setting.57,135
Low-dose usage was previously recommended to improve
renal and splanchnic blood ﬂow and renal function; how-
ever, more recent studies and meta-analyses failed to re-
inforce this beneﬁt.136–138 More recent data reported about
increased mortality related to dopamine administra-
tion,139–141 presuming a complex underlying mechanism.
Reduced gastrointestinal motility, mucosal pH, and oxygen
consumption have been reported about its use,142,143 in
some cases potentially intensifying ventilation–perfusion
mismatch,144 causing multiple anomalies in the thyroid
axis145,146 or resulting in immune dysfunction by reducing
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prolactin hormone secretion and attenuating the chemotac-
tic effect of IL-8 on neutrophil granulocytes.145,147,148
At doses of 3 to 20 µg/kg/minute, dobutamine increases
myocardial contractility and heart rate while decreasing SVR;
therefore, it can beused insteadoforwithmid-dosedopamine
in low CO associated with high or normal SVR.57,149–153
Low CO shock refractory to dopamine and/or dobuta-
mine may be reversed with epinephrine initiated at doses of
0.02 µg/kg/minute and titrated up to 1 µg/kg/minute,61,154–157
with some clinicians using it as ﬁrst-line inotrope in hypody-
namic shock due to the unfavorable side-effects of dopa-
mine.57 At low (<0.3 µg/kg/min) or high (>3 µg/kg/min)
doses, itdominantlyhasβandα adrenergiceffect, respectively.
Ideally, epinephrine should be given through central venous
access, but in emergency cases, intraosseous and peripheral
venous administration is also feasible.57 For a therapeutic
response, it should be titrated to achieve desired effect
due to its wide interpatient variability.158,159 Epinephrine
intensiﬁes gluconeogenesis and glycogenolysis, with its
hyperglycemic effect likely resulting in adverse outcomes. By
stimulating gluconeogenesis, epinephrine enhances lactate
shuttle to the liver, and plasma lactate concentration rises
and becomes independent of organ perfusion, possibly
impeding interpretation of the measured value.57
In the less prevalent dopamine-resistant high-CO and
low-SVR setting, norepinephrine should be titrated from
an initial dose of 0.02 µg/kg/minute to reach hemodynamic
support endpoints.57,160 In vasodilatory shock treatment,
vasopressin and terlipressin, both acting independent from
catecholamine receptor stimulation, might be an alterna-
tive.161–166 During vasopressor use, close hemodynamic
monitoring is recommended; increased SVR might lead to
deterioration of myocardial contractility and consequential
reduction of CO, potentially necessitating the use of inotropic
agents.57,157
In normotensive patients refractory to inotropic treat-
ment and having low CO and high SVR, nitrovasodilators can
be used to reduce ventricular afterload.57 Nitroprusside can
be titrated for the desired effect (0.5–10 µg/kg/minute).157
Type III phosphodiesterase inhibitor (milrinone, inamri-
none) use may be an alternative to increase myocardial
contractility and reduce SVR.167–169 Their main advantage
is a sustained effect even under β-adrenergic receptor down-
regulation and desensitization.57Having a long half-life, they
reach steady-state serum concentrations in up to several
hours, driving some clinicians to give a bolus loading dose.
Arrhythmia and hypotension owing to their use requires
withdrawal, with the latter potentially necessitating crystal-
loid or colloid ﬂuid bolus or vasopressor treatment.57,78 In
intractable myocardial dysfunction, levosimendan may be
considered as a last resort.170–172
Corticosteroids
In sepsis, hypothalamic–pituitary–adrenal axis affects in-
ﬂammation through leukocytes, cytokines, and nitric-oxide
production;173 however, inﬂammatory cytokines might
cause simultaneous insufﬁcient adrenal output by suppres-
sion of the cortisol response to adrenocorticotropin and
may result in peripheral glucocorticoid resistance by redu-
cing the number and afﬁnity of receptors.174–176 In sepsis,
corticosteroid treatment suppresses cytokine production
and increases sensitivity of the cardiovascular system to
endogenous and exogenous catecholamines, thereby im-
proving myocardial contractility, SV, SVR, and effective
circulating blood volume.177 Although hydrocortisone treat-
ment might be life-saving,178–180 yet data on the exact effect
on mortality are still controversial.57,181–183 As per current
recommendations, steroid treatment should be reserved
for children with catecholamine-resistant septic shock and
suspected (e.g., severe septic shock with purpura, prior
steroid use due to chronic illness, pituitary or adrenal
abnormalities) or proven (deﬁned as random total cortisol
level less than 18 µg/dL) adrenal insufﬁciency.16,57
Elimination of Pathogens
Early antibiotic therapy is crucial in the treatment of septic
patients, possibly initiated within an hour.16 In adults with
septic shock, each hour delay from detection increased
mortality by 7.6%,184whereas a retrospective study reported
signiﬁcantly higher mortality rates in children receiving
antibiotic therapy initiated beyond 3 hours.185
Empirical antibiotic therapy should cover sensitivity of
the most probable pathogens; well-selected therapy signiﬁ-
cantly reduces the risk of mortality.186 Selection of the active
ingredient is complex. Patient age, history (underlying
illnesses, immune status, drug hypersensitivity), where
primary infection was acquired (community-acquired or
nosocomial), results of previous cultures (sensitivity of
pathogens inducing colonization or conﬁrmed infection),
prior antibiotic treatment (last 3 months), and local anti-
biotic resistance should be considered during decision-
making. Additionally, it is important for antibiotics to pene-
trate in adequate amounts into the target organ or tissue.16
In sepsis treatment, bactericidal agents should be preferred
over bacteriostatic ones, given that former drugs kill patho-
gens independent of the patient’s immune system.23 There
are no speciﬁc guidelines on empirical antibiotic therapy;
the most frequent combinations are listed in ►Table 6.
If possible, consultation with a pediatric infectologist is
recommended.16
Difﬁculties during or contraindications to culture collec-
tion (e.g., hemodynamic instability and/or coagulopathy
during lumbar puncture) must not delay treatment initia-
tion; nevertheless, successful sampling is indispensable for
de-escalation of subsequent antibiotic therapy. During initial
ﬂuid resuscitation and combined antibiotic therapy, drugs
given as bolus must be prioritized over infused active
ingredients regarding administration sequence; concurrent
use of antibiotics and ﬂuid therapy can be facilitated through
a second vascular access.16
De-escalationofempirical treatment shouldbedonewithin
3 to 5 days after obtaining culture results; for subsequent
infection management, the most effective monotherapy must
be selected (except aminoglycoside monotherapy). Antibiotic
therapy should be maintained for 7 to 10 days, but in cases
of slow clinical response, immunodeﬁciency, source control
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problems, or Staphylococcus aureus sepsis, longer treatment
periodsmight benecessary. During antibiotic therapyof septic
patients, hepatic and renal dysfunction, ﬂuid compartments,
and redistribution altered by ﬂuid resuscitation may necessi-
tate dose modiﬁcation. Also, improving efﬁcacy and minimiz-
ing toxicity risk can be promoted by measuring serum
concentrations.16,23
Source control is an important component of sepsis
treatment,16 including debridement of various infected,
necrotic tissues, drainage of infected ﬂuids, rapid removal
of objects, and foreign bodies identiﬁed as the infection
source, and, through restoration of anatomic integrity and
function, it aims to eliminate further contamination.187
During the intervention, along with beneﬁt from reducing
the infectious inoculum, potential hazards and complica-
tions of the intervention and associated transport must be
considered.188,189
Immunoglobulins
Adjuvant treatment of sepsis with intravenous immunoglo-
bulin (IVIG) seemed highly promising earlier; however, more
recent results are controversial.190–198 Most of the available
studies have small sample size and some have methodolo-
gical ﬂaws. A large randomized, controlled trial (RCT) for the
treatment of sepsis in adults and a larger one in newborns
found no beneﬁt for IVIG.199,200 Due to its potential toxin-
neutralizing effect and an inﬂuence on facilitating opsoniza-
tion of Streptococci, the use of polyclonal immunoglobulin
was recommended previously in invasive group A Strepto-
coccal infections.198,201,202 Based on our current knowledge,
the beneﬁt of IVIG is doubtful in this case and its use may be
considered in refractory toxic shock syndrome.16
Red Blood Cell Transfusion and Treatment of
Disseminated Intravascular Coagulation
Restoration of massive cytokine release, myocardial depres-
sion, capillary leak, and abnormal tissue oxygen delivery due
to acidosis, each associated with sepsis, by normalizing CO
and hemoglobin levels is a cornerstone of therapy.16,57,203
No optimal hemoglobin concentration is known for critically
ill children.16,203,204 For adults, efﬁcacy analyses of goal-
directed therapy showed better outcomes if central venous
oxygen saturation could be maintained above 70% in
the ﬁrst 6 hours following presentation (protocol included
Table 6 Suggested initial empiric antimicrobial regimens
Situation Initial empiric antimicrobial regimen Alternative regimen
Children without
comorbidities (>2–3 mo)
Piperacillin (or ampicillin) þ β-lactamase
inhibitor
Ampicillin þ cefotaxime
Cefotaxime or ceftazidime 
aminoglycoside
Carbapenem
Nosocomial infection Piperacillin þ β-lactamase inhibitor Ceftazidime  aminoglycoside 
glycopeptide (in case of possible
MRSA or MRSE infection)
Carbapenem
Immunosuppression, neutropenia Piperacillin þ β-lactamase inhibitor Ceftazidime þ aminoglycoside 
glycopeptide (in case of possible
MRSA or MRSE infection)
Ceftazidime
Meropenem
Suspected urosepsis or
pyelonephritis
Ampicillin þ aminoglycoside Cefotaxime or ceftazidime þ
ampicillin (in case of possible
enterococcal infection) 
aminoglycoside
Possible GI source Cefotaxime þ metronidazole Piperacillin þ β-lactamase inhibitor
Ampicillin þ β-lactamase inhibitor Meropenem
Catheter-related infection Cefuroxime Consider adding rifampicin
Ceftazidime or carbapenem þ glycopeptide
(in case of possible MRSA or MRSE infection)
Possible MRSA infection Add vancomycin to the empiric antibiotic regimen Linezolid or teicoplanin
Possible MRGN infection Meropenem Imipenem
Severe sepsis or septic shock Meropenem  vancomycin  aminoglycoside Cefotaxime (in case of conﬁrmed
meningococcal meningitis)
Possible fungal infection Echinocandin (micafungin or caspofungin) Liposomal amphotericin
Abbreviations: GI, gastrointestinal; MRGN, multiresistant gram-negative bacteria; MRSA, methicillin-resistant Staphylococcus aureus; MRSE,
methicillin-resistant Staphylococcus epidermidis.
Source: Adapted from Sepsis (außer neonatale Early-onset-Sepsis). In: Berner R, Forster J, Bialek R, Borte M, DGPI - Deutsche Gesellschaft für
Pädiatrische Infektiologie. DGPI Handbuch. Infektionen bei Kindern und Jugendlichen. Stuttgart: Thieme; 2013:776–784.
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transfusion to attain hematocrit levels of 30).205 Earlier
recommendations for intensive therapy suggested higher
hemoglobin goals for septic children requiring intensive
care.206,207 In hemodynamically stable, critically ill children,
restrictive (hemoglobin threshold of 7 g/dL for red blood cell
transfusion) transfusion strategy was as safe as liberal strat-
egy (hemoglobin threshold of 9.5 g/dL for red blood cell
transfusion).204,208 An RCT on early goal-directed therapy of
childhood septic shock conﬁrmed better survival if 10 g/dL
was selected as transfusion cutoff.68 Accordingly, hemoglo-
bin goal is 10 g/L in hemodynamically unstable septic
children during resuscitation, with this threshold being
lower at 7 g/dL in stable patients.16
Disseminated intravascular coagulation is commonly
observed in severe sepsis and septic shock.209 Therapeutic
options are controversial and lack validation.210Routine use of
replacement therapy is not recommended, neither in case
of mild clinical signs of bleeding,211 but to stop clinically
0 min
5 min
15 min
60 min
- Recognize decreased mental status and poor perfusion
- Maintain patent airway
- Give oxygen via face mask with reservoir
- Assist breathing with bag-valve-mask ventilation if required
- Establish i.v. or i.o. access
- Give boluses of 20mL/kg isotonic saline or balanced crystalloid up to 
60mL/kg unless rales and/or hepatomegaly develops
- Begin antibiotics
- Correct hypoglycemia and hypocalcemia
Shock not reversed?
- Begin dopamine (5-10mcg/kg/min) or epinephrine (0.05-0.4mcg/kg/ 
min)
- Use ketamine and atropine for obtaining central venous access and 
airway if required
- Establish arterial monitoring
- Cold shock: titrate dopamine (5-10mcg/kg/min) and/or dobutamine 
(5-15mcg/kg/min) and/or epinephrine (0.05-0.4mcg/kg/min)
- Warm shock: titrate norepinephrine (0.05-0.4mcg/kg/min)
Shock not reversed?
- Admit to PICU
- Give hydrocortisone (50mg/m2/day)  if at risk for absolute 
adrenal insufficiency
- Monitor CVP, attain normal MAP-CVP and ScvO2
Cold shock with normal blood 
pressure
- Titrate fluid or give RBC 
transfusion if hgb<10g/dL
- Add vasodilator or type III 
PDE inhibitor with volume 
loading
- Consider levosimendan
Cold shock with low blood 
pressure
- Titrate fluid or give RBC 
transfusion if hgb<10g/dL
- Consider norepinephrine
- Consider levosimendan
Warm shock
- Titrate fluid or give RBC 
transfusion if hgb<10g/dL
- Titrate norepinephrine up to 
0.6mcg/kg/min
- Consider vasopressin or 
terlipressin
Shock not reversed?
- Treat pericardial effusion, pneumothorax and intra-abdominal pressure >12 Hgmm
- Place pulmonary artery catheter or consider PICCO, FATD catheter and/or doppler ultrasound and direct 
fluid, inotrope, vasopressor, vasodilator, and hormonal therapies to attain normal MAP-CVP and 3.3 < CI 
< 6.0 L/min/m2 
90 min
120 min
Refractory shock: ECMO
Fig. 1 Stepwise management of hemodynamic support in infants and children with septic shock.
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signiﬁcant bleeding, the use of platelet, fresh frozen plasma,
and cryoprecipitate infusions might be necessary.212,213
Based on the few data available, protein C concentrate
might be effective in severe sepsis associated with purpura
fulminans. Improved microcirculation, moreover, lower
amputation and skin graft rates were reported about its
use with no adverse reactions.214–216
Glucose Control
In septic children, disorders of glucose homeostasis are fre-
quent. Due to peripheral insulin resistance and enhanced
gluconeogenesis, there is high risk of hyperglycemia, which
might be further enhanced by excessive sugar intake through
infusions and total parenteral nutrition.217 Neutrophil and
macrophagefunction,aswell aswoundhealingaredeteriorated
by hyperglycemia, while increasing infection and thrombosis
risk.218,219 Higher mortality rates and longer hospitalization
were reported for hyperglycemia in critically ill children,220–222
with few and controversial available data on the treatment of
hyperglycemia developed during sepsis.203,223–225Until results
of more recent trials become available, insulin therapy should
be initiatedonly forbloodglucose levelsabove180mg/dL, along
with close blood glucose monitoring to avoid hypoglycemia, in
accordance with recommendations for treatment of adults.16
Fornote, insulindemandusually declines rapidly 18hours from
shock initiation.57 Hypoglycemia can have devastating neuro-
logic consequences and should be diagnosed early and treated
immediately. Once initial hypoglycemia is resolved, children
should receive10%dextrose innormal salineensuringaglucose
intake of 2 to 8 mg/kg/minute depending on age to maintain
euglycemia.16,57
Refractory Shock
In children with refractory shock, potential associated
conditions negatively inﬂuencing outcome must be revealed.
Pneumothorax, pericardial effusion, and intra-abdominal
hypertension may equally be mechanic causes of shock persis-
tence, and their treatment must not be delayed after diagnosis.
In adrenal insufﬁciency or hypothyroidism, adequate hormone
substitution should be performed. In refractory shock, expan-
sionofempiricalantibioticcoverage,drainage,anddebridement
of the necrotic areas might be necessary. Immunosuppressive
treatment should be withheld; in neutropenia, granulocyte
colony-stimulating factor should be used where appropriately
indicated. Excessive bleedingmost frequently developed due to
disseminated intravascular coagulation might indicate use of
RBC and blood products.16,57 If hemodynamic support end-
points cannotbe reachedby treating these reversible causesand
in associated refractory respiratory failure, extracorporeal
membrane oxygenation may be used as a last resort.226–230
Conclusion
Therapeutic algorithmof childhood sepsis and septic shock is
summarized in►Fig. 1. Success of sepsis care is improved by
properly organized emergency care and compliance with
internationally accepted treatment guidelines. It is impor-
tant to note that most pediatric sepsis cases can be pre-
vented; therefore, effective prevention based on screening
programs, vaccination, and infection control provisions is an
exceedingly important strategic move.
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